Mirae Asset Global Investments Co., Ltd. Akero Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,326 shares of AKRO stock, worth $104,856. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,326

Previous 2,511 7.37%

Holding current value

$104,856

Previous $72,000 11.11%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$26.75 - $35.28 $4,948 - $6,526	-185 Reduced 7.37%	2,326 $64,000
Q3 2024 Oct 23, 2024	BUY	$21.45 - $29.34 $9,566 - $13,085	446 Added 21.6%	2,511 $72,000
Q2 2024 Jul 30, 2024	SELL	$18.31 - $24.62 $431,987 - $580,859	-23,593 Reduced 91.95%	2,065 $48,000
Q1 2024 May 01, 2024	SELL	$17.76 - $31.18 $252,671 - $443,597	-14,227 Reduced 35.67%	25,658 $648,000
Q4 2023 Jan 24, 2024	BUY	$11.38 - $50.33 $108,872 - $481,507	9,567 Added 31.56%	39,885 $931,000
Q3 2023 Oct 26, 2023	BUY	$41.19 - $52.25 $144,123 - $182,822	3,499 Added 13.05%	30,318 $1.53 Million
Q2 2023 Aug 10, 2023	BUY	$36.89 - $56.88 $159,807 - $246,404	4,332 Added 19.26%	26,819 $1.25 Million
Q1 2023 May 04, 2023	BUY	$37.27 - $50.24 $231,185 - $311,638	6,203 Added 38.09%	22,487 $860,000
Q4 2022 Feb 09, 2023	BUY	$33.44 - $54.8 $110,586 - $181,223	3,307 Added 25.48%	16,284 $892,000
Q3 2022 Nov 10, 2022	BUY	$10.15 - $34.05 $131,716 - $441,866	12,977 New	12,977 $442,000

Others Institutions Holding AKRO

# of Institutions

209

Shares Held

66.9M

Call Options Held

321K

Put Options Held

558K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.09B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Akero Therapeutics, Inc. Transaction History